დასაწყისი · კატალოგი · პროფილი · ცხრილი
დანამატები BODY HANDBOOK
დანამატები · §548
Saffron
A bright-red kitchen spice sold by the gram at gold-comparable prices that, at twenty-eight milligrams a day of a standardised extract, matched fluoxetine for mild-to-moderate depression in head-to-head trials and cut PMS severity for three women in four. The marketing pitch you'll meet online is wider than that — skin glow, hair, weight loss, energy, focus. The honest picture is narrower and more useful: a real botanical option for the reader whose low mood isn't quite an SSRI conversation, for the reader on one whose sex life it took, and for anyone losing three days every month to PMS. Fifteen dollars a month, eight weeks to know.
გააკეთე · ყოველდღე მტკიცებულება განვითარებადი თავი დანამატები

The mood lift is the line: two capsules a day of standardised extract matched fluoxetine in mild-to-moderate depression across several head-to-head trials and beat placebo in nearly every trial that's been run. PMS severity drops for three women in four. The sexual side effects that drive most SSRI quitting often get rescued by adding it. Cheap to try; eight weeks to know if you're a responder. The catches: pregnancy is out, severe depression needs a clinician, and the threads in your spice rack aren't a supplement.

Saffron's red stigmas — three per flower, weighing about a tenth of a gram all together — contain three molecules that do most of the work: crocin, the red pigment; safranal, the aroma compound that makes saffron smell like saffron; and crocetin, the small fragment of crocin that crosses into the bloodstream. They behave a lot like a polypharmacological antidepressant. In animal and binding studies they inhibit monoamine oxidase A, slow the reuptake of serotonin, noradrenaline, and dopamine the way SSRIs and SNRIs do, nudge the BDNF growth signal that sits downstream of nearly every effective mood drug, and antagonise NMDA receptors the way ketamine does — at a much smaller scale than any of those, but on most of the same levers Lopresti and Drummond 2014. The retinal effect runs on a separate track: crocetin reaches the back of the eye through the choroidal circulation and scavenges the reactive oxygen molecules that drive age-related macular degeneration. The same compound, two different jobs.

What the trials actually show

For mild-to-moderate depression, the trial pattern is unusually consistent. Two divided doses of standardised stigma extract a day, six weeks, and the Hamilton Depression scale falls by roughly a third — beating placebo in every Iranian trial that ran and matching fluoxetine 20 mg in the head-to-head Akhondzadeh et al. 2005 Noorbala et al. 2005. By 2019 the meta-analysis had pooled eleven trials and roughly five hundred patients and found the same direction: significantly better than placebo, statistically indistinguishable from standard antidepressants Marx et al. 2019. The honest caveat is that most of this evidence is Iranian, the trials are small, and the largest pooled dataset is still smaller than a single phase-three SSRI registration trial. The replications in Australian adolescents and in Western adults experiencing low mood have come in positive too Lopresti et al. 2018.

For PMS, the head trial is concrete enough to anchor on by itself.

For SSRI-induced sexual dysfunction — the side effect that drives more discontinuation than any other — two trials from the same Tehran group added 30 mg of saffron to fluoxetine in men and in women. In both, the relevant index scores improved on saffron and not on placebo: erectile function and intercourse satisfaction in men Modabbernia et al. 2012; arousal, lubrication, and pain in women Kashani et al. 2013. The trials were small and the effect didn't reach every domain — desire and orgasm were unchanged — but the rescue is real for arousal-side problems specifically.

The other claims are real but smaller. For early age-related macular degeneration, 20 mg a day for three months improved focal-ERG retinal-function scores and lifted Snellen visual acuity slightly in an Italian group's crossover trial; the gains held over a fourteen-month follow-up, and an independent Australian group replicated the visual-acuity signal Falsini et al. 2010 Piccardi et al. 2012 Broadhead et al. 2019. For appetite, a specific extract called Satiereal cut snacking by more than half and produced about 1.5 kg of fat loss over eight weeks in mildly overweight women — modest but real, and from a single industry-sponsored trial Gout et al. 2010. For sleep, four weeks of evening saffron improved the Insomnia Severity Index in a small Australian trial Lopresti et al. 2020. None of these are at the level of the depression and PMS signals. They are the secondary reasons, not the headline.

The dose, and how to actually run a trial

Across nearly every indication, the dose has converged on the same number: 28 to 30 milligrams a day of a standardised stigma extract, split into a morning and evening dose, taken with food, run for at least six to eight weeks before judging whether you're a responder. Anything shorter is too soon — the Hamilton Depression curve in the trials separates from placebo around week three or four and keeps widening through week six. The onset window is closer to an SSRI's than to aspirin's, and the same patience applies.

When not to take it

The hard line is pregnancy. At very high doses — far above any supplement, but inside the range of traditional Persian medicinal preparations — saffron stigma stimulates uterine contractions and animal models show fetal toxicity. Supplement doses are nowhere near that threshold, but no safety trial in pregnant women has been done or will ever ethically be done, and the medical tradition that knew the plant longest warned against it explicitly Hosseinzadeh and Nassiri-Asl 2014. Breastfeeding inherits the same caution. Bipolar disorder is the second caveat: any compound acting on monoamine oxidase carries a theoretical risk of tipping a mood into mania, and saffron has not been studied in bipolar populations — treat it the way you'd treat any antidepressant.

Who this is most clearly for

Two reader pictures the trial numbers describe most cleanly.

For women with significant PMS — irritability that scuttles a date night, breast tenderness that sits under every workout, the depressive dip on day 25 that you've learned to schedule around — saffron at 30 mg/day through two full cycles is the option the data most cleanly supports. Three in four felt the difference in the Agha-Hosseini trial; one in twelve felt it on placebo Agha-Hosseini et al. 2008. The wider PMS landscape has its own merits — luteal-phase SSRIs, magnesium, B6, calcium, cycle-tracked exercise — and saffron isn't the only option. It's the one that doesn't need a prescription, isn't a hormone, and travels with the cleanest side-effect profile.

For anyone on an SSRI and quietly losing their sex life to it — and that's roughly half of people on one — adding saffron is the rescue with the best trial evidence. It isn't perfect: desire and orgasm don't always come back, but arousal, lubrication, and erectile function usually do Kashani et al. 2013 Modabbernia et al. 2012. The pre-condition is that the SSRI itself is otherwise working — saffron is the add-on, not the swap.

For the reader with low-grade depression who has either tried an SSRI and disliked the trade or never quite qualified for one, saffron is a serious eight-week trial. Mild-to-moderate depression is the slice of the evidence base; severe depression isn't.

Three things saffron isn't

The threads in your spice rack are not the supplement. A paella's worth of saffron carries a fraction of the standardised extract's dose, and the bulk-spice market is heavily adulterated besides (see failure modes below). The mood and PMS trials are all run on extract; the cooking spice is for cooking.

Saffron is not a "natural SSRI" in the lay sense of weaker-but-safer. The receptor profile is actually broader than any SSRI — it touches MAO-A, every monoamine transporter, NMDA, GABA, and BDNF — and the trial evidence is specifically for mild-to-moderate depression. Severe depression, psychotic depression, and treatment-resistant depression have not been adequately studied; the right assumption is that this is the wrong tool for them.

The skin-glow, hair-growth, libido-without-an-SSRI-baseline, and limitless-energy claims that cluster around saffron in the supplement-marketing universe do not have the trial backing that depression and PMS do. They are extrapolation from the molecule's antioxidant chemistry, not findings.

Why a trial seems to fail when it does

Three reasons, in roughly descending order of frequency.

  • The product is adulterated. Independent testing of bulk saffron has found 30–40% of samples padded with safflower, marigold, or beet, and even saffron classified to the ISO standard can carry up to a fifth of its weight in adulterants invisible to that standard Petrosino et al. 2018. A standardised extract with HPLC-verified active-compound content — affron, Satiereal, safr'Inside — sidesteps this. A $5 bottle of "saffron extract" with no standardisation listed is a different product, and may be a mostly-red-coloured-plant-matter product.
  • The trial is too short. Most people quit at week three. So would most people on an SSRI, at the point the curve is just starting to bend. Eight weeks is the minimum honest test.
  • The indication is wrong. Saffron has been tested in mild-to-moderate depression, PMS, SSRI sexual-side-effect rescue, retinal preservation, snack suppression, and sleep. For severe depression, generalised anxiety as a standalone, weight loss without an emotional-snacking pattern, or the assorted lookmaxxing claims, the evidence is thin and the result will be too.

What month two looks like, if you respond

The trials don't promise a transformation, and the dek shouldn't either. What they project, for the readers the evidence covers, is something specific you'd been losing, given back.

The low-mood reader gets to week six and notices the morning weight has lifted — not gone, but no longer the thing they wake up under. The session at the gym they kept skipping, they're doing again. They haven't gained weight, haven't lost interest in sex, the emotional flatness they remember from a previous antidepressant trial hasn't arrived Marx et al. 2019.

The PMS reader gets to day 25 of the second cycle and realises she's been bracing for the dip and it didn't come. Or it came and lost its tooth. By the third cycle the relationship that used to fray on days 24–28 stops fraying; the partner notices before she tells him Agha-Hosseini et al. 2008.

The SSRI-with-sexual-dysfunction reader finds intercourse mostly works again by week four. Desire and orgasm aren't back to baseline; arousal and the rest of the response cycle largely are. The relationship survives the medication instead of being slowly bartered against it Kashani et al. 2013 Modabbernia et al. 2012.

None of this is a transformation. The honest verb is recover — a specific thing the depression, the cycle, or the medication had been taking from you, returned. For about half of responders, that's enough to keep taking it.

Adjacent ground

If saffron is the question, these are usually the next questions.

  • SSRIs themselves — the comparator the saffron depression trials are built around. The trade-off shape worth understanding before deciding either way.
  • Other PMS approaches — luteal-phase SSRIs, magnesium, B6, calcium, and the cycle-tracked exercise and sleep pieces. Saffron is one option, not the field.
  • Light therapy and morning sunlight for the low-mood reader with a seasonal pattern.
  • AREDS-2 for established AMD. The retinal saffron signal is interesting but doesn't displace what's already guideline-grade.
  • SAMe and St. John's wort — the other botanical antidepressants with their own evidence shapes. Saffron's the cleanest of the three on side effects and trial replication, but the field overlaps.
·
548